Earnings per Share (EPS) of -$0.056 missed the estimated EPS of -$0.05, indicating a shortfall in profitability.Reported revenue of $725,000 exceeded the estimated $714,000, showcasing higher-than-anticipated sales performance.Financial metrics reveal a price-to-sales ratio of 17.31 and a debt-to-equity ratio of 0.82, highlighting investor expectations and moderate debt management.IceCure Medical Ltd. (NASDAQ: ICCM) specializes in minimally-invasive cryoablation technology for the local treatment of low-ris ...

IceCure Medical (NasdaqCM:ICCM) Q3 2025 Earnings Call November 19, 2025 10:00 AM ET Company ParticipantsMichael Polyviou - Head of Investor RelationsRonen Tsimerman - CFOEyal Shamir - CEOConference Call ParticipantsAnthony V Vendetti - AnalystOperatorGood morning, and thank you for standing by. Currently, all of the participants are in listen-only mode. After management's discussion, there'll be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like ...

IceCure Medical (NasdaqCM:ICCM) Q3 2025 Earnings Call November 19, 2025 10:00 AM ET Company ParticipantsMichael Polyviou - Head of Investor RelationsRonen Tsimerman - CFOEyal Shamir - CEOConference Call ParticipantsAnthony V Vendetti - AnalystOperatorGood morning, and thank you for standing by. Currently, all of the participants are in listen-only mode. After management's discussion, there'll be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like ...

IceCure Medical (NasdaqCM:ICCM) Q3 2025 Earnings Call November 19, 2025 10:00 AM ET Speaker2Good morning, and thank you for standing by. Currently, all of the participants are in listen-only mode. After management's discussion, there'll be a question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference over to Michael Polyviou. Please go ahead.Speaker0Thank you, Ella, and welcome to IceCure Medical's conference call to review the finan ...

Core Insights - IceCure Medical (ICCM) has received FDA marketing authorization for its ProSense cryoablation system, the first minimally invasive treatment for low-risk breast cancer in women aged 70 and above, positioning it as an alternative to lumpectomy [1][8] - The approval opens commercial opportunities in the U.S. and validates IceCure's leadership in cryoablation technology, with established reimbursement pathways enhancing adoption prospects [2][4] Company Summary - Following the FDA announcement, ICCM shares rose by 12% in after-market trading, although the stock has seen a year-to-date decline of 12.4% compared to the industry’s 5.2% growth and the S&P 500's 15.2% gain [3] - ICCM's market capitalization stands at $66.2 million, with an expected earnings growth of 26.7% in 2025 [5] Competitive Position - The FDA authorization significantly enhances IceCure's commercial outlook by granting access to the U.S. breast cancer treatment market, establishing a competitive moat against rivals who will face higher clinical data requirements for entry [4][10] - ProSense benefits from a CPT III reimbursement code covering $3,800 of facility costs, with potential for expanded coverage as adoption increases, positioning IceCure for accelerated revenue growth and market penetration [10] Clinical Validation - The FDA's decision was supported by robust clinical data from the ICE3 trial, demonstrating outcomes comparable to traditional surgical methods while offering a quicker, minimally invasive procedure [9] - IceCure plans to conduct a post-market study involving around 400 patients across 30 sites in the U.S. to further validate long-term efficacy, which will also serve as commercial centers for efficient rollout [9] Industry Outlook - The global cryoablation for cancer market was valued at $3.5 billion in 2024 and is projected to grow at a CAGR of 6.1%, reaching $5.8 billion by 2033, driven by rising cancer incidence and an aging population [11][12] - The increasing adoption of cryoablation for smaller tumors is a major driver of market expansion, as it offers fewer side effects compared to traditional treatments [12]